Technical Analysis for INO - Inovio Pharmaceuticals, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 4.32 | 3.10% | 0.13 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| NR7-2 | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| NR7 | Range Contraction | 3.10% | |
| Inside Day | Range Contraction | 3.10% | |
| Wide Bands | Range Expansion | 3.10% | |
| Gapped Up | Strength | 3.10% | |
| Oversold Stochastic | Weakness | 3.10% | |
| Wide Bands | Range Expansion | 7.73% |
| Alert | Time |
|---|---|
| Possible NR7 | 2 days ago |
| Up 3% | 2 days ago |
| 60 Minute Opening Range Breakout | 2 days ago |
| Up 2% | 2 days ago |
| Rose Above Previous Day's High | 2 days ago |
Free Daily (Stock) Chart Reading
- Earnings date: 11/14/2024
Inovio Pharmaceuticals, Inc. Description
Inovio Pharmaceuticals, Inc., together with its subsidiaries, engages in the discovery and development of synthetic vaccines and immune therapies focusing on cancers and infectious diseases. The company's DNA-based SynCon technology enables the design of vaccines capable of providing cross-protection against new, unmatched strains of pathogens, such as influenza. Its electroporation DNA delivery technology uses controlled electrical pulses to enhance cellular DNA vaccine uptake. The company's clinical programs include human papillomavirus/cervical cancer (therapeutic), avian influenza (preventive), prostate cancer (therapeutic), leukemia (therapeutic), hepatitis C virus, hepatitis B virus, human immunodeficiency virus, and malaria vaccines. It is also advancing preclinical research for a seasonal/pandemic influenza vaccine, as well as other products. Inovio Pharmaceuticals, Inc. has collaboration and license agreements with VGX International, Merck, and ChronTech. The company was formerly known as Inovio Biomedical Corporation and changed its name to Inovio Pharmaceuticals, Inc. in May 2010. Inovio Pharmaceuticals, Inc. was founded in 1983 and is headquartered in Blue Bell, Pennsylvania.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Infectious Diseases Prostate Cancer Clinical Research Coronavirus Influenza Vaccines Hepatitis B Leukemia Vaccination Hepatitis C Immunodeficiency Hepatitis C Virus Virus Hepatitis B Virus Malaria Papillomavirus Virology Influenza Vaccine Cervical Cancer Avian Influenza Electroporation
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 14.748 |
| 52 Week Low | 3.85 |
| Average Volume | 367,005 |
| 200-Day Moving Average | 8.58 |
| 50-Day Moving Average | 5.29 |
| 20-Day Moving Average | 4.73 |
| 10-Day Moving Average | 4.11 |
| Average True Range | 0.26 |
| RSI (14) | 35.90 |
| ADX | 45.57 |
| +DI | 10.23 |
| -DI | 28.93 |
| Chandelier Exit (Long, 3 ATRs) | 5.01 |
| Chandelier Exit (Short, 3 ATRs) | 4.64 |
| Upper Bollinger Bands | 6.05 |
| Lower Bollinger Band | 3.42 |
| Percent B (%b) | 0.34 |
| BandWidth | 55.53 |
| MACD Line | -0.42 |
| MACD Signal Line | -0.41 |
| MACD Histogram | -0.0082 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.53 | ||||
| Resistance 3 (R3) | 4.51 | 4.42 | 4.49 | ||
| Resistance 2 (R2) | 4.42 | 4.37 | 4.43 | 4.48 | |
| Resistance 1 (R1) | 4.37 | 4.34 | 4.40 | 4.39 | 4.47 |
| Pivot Point | 4.29 | 4.29 | 4.30 | 4.30 | 4.29 |
| Support 1 (S1) | 4.23 | 4.23 | 4.26 | 4.25 | 4.17 |
| Support 2 (S2) | 4.15 | 4.20 | 4.16 | 4.16 | |
| Support 3 (S3) | 4.10 | 4.15 | 4.15 | ||
| Support 4 (S4) | 4.11 |
